Bioactive Glass Bone Grafts with Multi-Scale Pores
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current bone graft implants fail to provide reliable and consistent results due to issues such as rapid degradation, inadequate mechanical integrity, and improper porosity and pore size distribution, leading to suboptimal bone tissue growth and remodeling.
Innovation Solution
The development of porous, composite bone graft implants made from bioactive glass fibers and granules, with varying resorption rates and pore size distributions, providing a synergistic combination of structural and functional features for optimal cell proliferation and tissue growth, including a fibrous scaffold with interconnected macro, meso, and nano pores.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of moving object
If the scaffold degrades rapidly to allow new tissue emergence, then bone tissue formation is initiated, but the scaffold degrades faster than bone tissue maturation, resulting in poor clinical outcomes
Solution Approach 1:
The patent applies parameter changes by precisely controlling the porosity (50-90%) and pore size distribution (micro-pores 1-10 μm, meso-pores 10-100 μm, macro-pores 100-1000 μm) of the bioactive glass scaffold to regulate its degradation rate. These parameter optimizations ensure the scaffold degrades at a controlled pace that matches bone tissue maturation, preventing premature collapse while enabling timely tissue formation.
Solution Approach 2:
The patent employs composite materials by creating a multi-scale porous structure within the bioactive glass matrix that combines different pore sizes and types. This composite pore architecture enables simultaneous functions of nutrient transport, cell infiltration, and controlled degradation, achieving reliable clinical outcomes through synergistic material design.
2Reliability
If the scaffold porosity is increased to allow vascularization and cell infiltration, then bone tissue growth is promoted, but the mechanical integrity of the scaffold is reduced
Solution Approach 1:
The patent applies local quality by creating distinct pore size zones within the scaffold structure. The surface region contains micro-pores for cell attachment, the intermediate region contains meso-pores for nutrient transport, and the core region contains macro-pores for vascularization. This spatial differentiation of pore qualities allows each region to fulfill specific functions while collectively maintaining overall structural integrity.
Solution Approach 2:
The patent utilizes porous materials by incorporating a hierarchical pore network (micro-, meso-, and macro-pores) within the bioactive glass scaffold. This porous structure enables simultaneous achievement of high porosity (50-90%) for tissue ingrowth and adequate mechanical strength through the optimized pore architecture that prevents catastrophic structural failure.
3Reliability
If the scaffold pore size is optimized for cell attachment and vascularization, then bone healing is enhanced, but the structural support capability is compromised
Solution Approach 1:
The patent applies dimensionality change by transitioning from a single pore size to a multi-scale pore size distribution spanning three orders of magnitude (1-1000 μm). This dimensional expansion in pore size space allows the scaffold to simultaneously provide structural support through the macro-pore framework while enabling cell attachment via micro-pores and vascularization through meso-pores, resolving the trade-off between mechanical support and biological functionality.
Data Source
Figure 1A~1C
Figure 2~4
Figure 5A~5C
AI summary
Bioactive porous bone graft implants in various forms suitable for bone tissue regeneration and/or repair, as well as methods of use, are provided. The implants are formed of bioactive glass and have an engineered porosity. The implants may take the form of a putty, foam, fibrous cluster, fibrous matrix, granular matrix, or combinations thereof and allow for enhanced clinical results as well as ease of handling.